Novartis gets EU approval for Cushing's drug

ZURICH Wed Apr 25, 2012 6:32am BST

A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. REUTERS/Arnd Wiegmann

A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011.

Credit: Reuters/Arnd Wiegmann

Related Topics

Quotes

   

ZURICH (Reuters) - Swiss drug maker Novartis AG (NOVN.VX) said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing's disease, a rare hormonal disorder.

Signifor, which is designed for Cushing's disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January.

Cushing's is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.

FILED UNDER: